Oct 17, 2022
Dan Brounstein is Chief Strategy Officer at Saluda Medical where he is using his 15 years of Spinal Chord Stimulator experience to help deliver closed-loop pain relief directly to the spinal cord.
***This podcast is sponsored by Iris Biomedical, check out their Neurotech Startup Services here***
Top 3 Takeaways:
"There's a lot of literature on loss of efficacy? It's just a therapy issue. When you deliver open-loop therapies blind across a neural target, you're ultimately going to create, over-stimulation in a lot of times under stimulation. On top of that, over time things change"
0:45 " Do you want to introduce yourself and the company better than I just did?"
6:00 "Your guys' device reprograms on its own? And then what signals does it take in and how does it change the stimulation patterns based on that?"
9:00 Iris Biomedical ad sponsorship
9:45 "What is your input and output for your guys' device?"
11:45 "In February of 2023, you guys got FDA approval for this. Do you wanna talk a little bit about this?"
14:15 "Is it like 5% better than open loop or is that something that's gonna be coming out published later?"
17:00 "Is there another indication?"
18:15 "The last I guess seven years for you has been very exciting. Is there anything on the horizon for the next seven years?"
20:15 "You guys have 300 people and have raised 200 million. What's it like working in such a big company"
22:45 "Is it getting too big for you?"
23:45 "What advice do you have for people in your situation?"
26:00 "Is there anything that we didn't talk about that you wanted to mention?"